Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Incyte Corporation
Symphogen A/S
Memorial Sloan Kettering Cancer Center
Quadriga Biosciences, Inc.
Eli Lilly and Company
Shionogi Inc.
Incyte Corporation
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
University of Chicago
Papworth Hospital NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
Pediatric Brain Tumor Consortium